IFP Advisors Inc Has $4.67 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

IFP Advisors Inc grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,252 shares of the company’s stock after purchasing an additional 1,873 shares during the quarter. IFP Advisors Inc’s holdings in Johnson & Johnson were worth $4,665,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in JNJ. IFS Advisors LLC increased its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $31,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $35,000. Finally, Activest Wealth Management bought a new stake in Johnson & Johnson in the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on JNJ shares. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Bank of America cut their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Finally, Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $163.69 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $394.11 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The stock has a fifty day moving average of $150.48 and a 200-day moving average of $156.02.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the firm earned $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. Johnson & Johnson’s payout ratio is presently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.